|
|
Correction Correction: Interleukin-6: a new therapeutic target1 Professor of Medicine, Chairman Division of Rheumatology, Medical University of Vienna, Vienna, Austria 2 Emeritus Professor of Rheumatology, The Kennedy Institute of Rheumatology Division, Imperial College, London, UK Arthritis Research & Therapy 2006, 8:407doi:10.1186/ar2065 The electronic version of this article is the complete one and can be found online at: http://arthritis-research.com/content/8/6/407
© 2006 BioMed Central Ltd CorrectionFollowing the publication of the above article [1], we noticed that due to an administrative oversight the Competing interests section was incomplete and should read as follows: JSS has received financial compensation from and served on advisory boards for Roche and is an investigator in clinical trials of tocilizumab. RNM has received consulting fees from Chugai; served on an ad hoc advisory board for Roche; and was responsible for the planning and preparation for publication of the Phase II European (CHARISMA) trial of tocilizumab with and without methotrexate. A patent for co-administration of methotrexate and tocilizumab for the treatment of rheumatoid arthritis, of which RNM is named as a co-inventor, has been applied for and fully assigned to Chugai. References
Have something to say? Post a comment on this article! |
|
|
|
 |  | Log on / register BioMed Central home | Journals A-Z | Feedback | Support | My details |
home | issues | articles | reports | supplements | weblinks | conferences | search | information | subscribe | my details |
on Google Scholar
|
|
| © 1999-2010 BioMed Central Ltd unless otherwise stated. Part of Springer Science+Business Media. |